2013


To access this material please log in or register

Register Authorize
2013/№1

New oral anticoagulants in prevention of cardio-embolic complications in patients with atrial fibrillation

Yavelov I. S.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: anticoagulants, thrombolytic therapy, atrial fibrillation

DOI: 10.18087/rhj.2013.1.1726

Nowadays, it is obvious that in patients with atrial fibrillation (AF), oral anticoagulants (apixaban, dabigatran or rivaroxaban), as well as traditional antagonists of vitamin K, can be administered to prevent cardio-embolic complications These new medicines possess a number of practical and clinical advantages over warfarin. At the same time, new approaches have some restrictions that do not allow using them in all AF patients who need anticoagulants. Taking into account the increased variety, choice of a drug for prevention thromboembolic complications in a certain patient is challenging and requires special knowledge and careful analysis of effects and problems, which can be expected from replacement of traditional warfarin by each of new oral anticoagulants.
  1. Camm AJ, Lip GYH, Schotten U et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (deve­loped with the special contribution of the European Heart Rhythm Association, endorsed by the European Association for Cardio-Thoracic Surgery). Eur Heart J. 2010;31 (19):2369–2429.
  2. Fuster V, Ryden LE, Cannom DS et al. ACC / AHA / ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114 (7):e257–354.
  3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131 (7):492–501.
  4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146 (12):857–867.
  5. Connolly SJ, Eikelboom J, Joyner C et al, for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364 (9):806–817.
  6. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367 (9526):1903–1912.
  7. Hohnloser SH, Pajitnev D, Pogue J et al, for the ACTIVE W Investigators. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. J Am Coll Cardiol. 2007;50 (22):2156–2161.
  8. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol. 2012;59 (16):1413–1425.
  9. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012;60 (8):738–746.
  10. Connolly SJ, Ezekowitz MD, Yusuf S et al, for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361 (12):1139–1151.
  11. Patel MR, Mahaffey KW, Garg J et al. for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365 (10):883–891.
  12. Granger CB, Alexander JH, McMurray JJ et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365 (11):981–992.
  13. Huisman MV, Lip GY, Diener HC et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost. 2012;107 (5):838–847.
  14. Hohnloser S. H, Oldgren J, Yang S et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation. 2012;125 (5):669–676.
  15. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority rando­mized controlled trials. Arch Intern Med. 2012;172 (5):397–402.
  16. Eriksson BI, Smith JJ, Caprini J et al. Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: Findings from four Phase 3 trials. Thromb Res 2012: doi:10.1016 / j.thromres.2012.05.014
  17. Canadian Cardiovascular Society 2010 Atrial Fibrillation Guidelines. Доступно в Интернет на сайте http://www.ccs.ca / guidelines / cc_library_e.aspx.
  18. Skanes AC, Healey JS, Cairns JA et al, and the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate / Rhythm Control. Can J Cardiol. 2012;28 (2):125–136.
  19. Connolly SJ, Pogue J, Eikelboom J et al, on behalf of the ACTIVE W Investigators. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation. 2008;118 (20):2029–2037.
  20. Wann LS, Curtis AB, Ellenbogen KA et al. 2011 ACCF / AHA / HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran). A Report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123 (10):1144–1150.
  21. You JJ, Singer DE, Howard PA et al. Antithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 (2 Suppl): e531S-75S.
  22. Beasley BN, Unger EF, Temple R. Anticoagulant options – why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364 (19):1788–1790.
Yavelov I. S. New oral anticoagulants in prevention of cardio-embolic complications in patients with atrial fibrillation. Russian Heart Journal. 2013;12(1):48-56

To access this material please log in or register

Register Authorize
Ru En